» Articles » PMID: 16894395

The Analysis of 51 Genes in DSM-IV Combined Type Attention Deficit Hyperactivity Disorder: Association Signals in DRD4, DAT1 and 16 Other Genes

Abstract

Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder, starting in early childhood and persisting into adulthood in the majority of cases. Family and twin studies have demonstrated the importance of genetic factors and candidate gene association studies have identified several loci that exert small but significant effects on ADHD. To provide further clarification of reported associations and identify novel associated genes, we examined 1,038 single-nucleotide polymorphisms (SNPs) spanning 51 candidate genes involved in the regulation of neurotransmitter pathways, particularly dopamine, norepinephrine and serotonin pathways, in addition to circadian rhythm genes. Analysis used within family tests of association in a sample of 776 DSM-IV ADHD combined type cases ascertained for the International Multi-centre ADHD Gene project. We found nominal significance with one or more SNPs in 18 genes, including the two most replicated findings in the literature: DRD4 and DAT1. Gene-wide tests, adjusted for the number of SNPs analysed in each gene, identified associations with TPH2, ARRB2, SYP, DAT1, ADRB2, HES1, MAOA and PNMT. Further studies will be needed to confirm or refute the observed associations and their generalisability to other samples.

Citing Articles

Multidimensional Comparison of Methylphenidate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children, a 12-Week, Open-Label, Head-to-Head Clinical Trial.

Chen L, Du W Psychiatry Investig. 2025; 22(2):140-147.

PMID: 40017277 PMC: 11878140. DOI: 10.30773/pi.2024.0204.


The dopamine hypothesis for ADHD: An evaluation of evidence accumulated from human studies and animal models.

MacDonald H, Kleppe R, Szigetvari P, Haavik J Front Psychiatry. 2024; 15:1492126.

PMID: 39619336 PMC: 11604610. DOI: 10.3389/fpsyt.2024.1492126.


Stimulant medication and symptom interrelations in children, adolescents and adults with attention-deficit/hyperactivity disorder.

van der Pal Z, Geurts H, Haslbeck J, van Keeken A, Bruijn A, Douw L Eur Child Adolesc Psychiatry. 2024; .

PMID: 39527154 DOI: 10.1007/s00787-024-02610-8.


Neurobiology of attention-deficit hyperactivity disorder: historical challenges and emerging frontiers.

Koirala S, Grimsrud G, Mooney M, Larsen B, Feczko E, Elison J Nat Rev Neurosci. 2024; 25(12):759-775.

PMID: 39448818 DOI: 10.1038/s41583-024-00869-z.


Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.

Kole I, Vural P, Yurdacan B, Alemdar A, Mutlu C Eur J Clin Pharmacol. 2024; 80(11):1773-1785.

PMID: 39158690 DOI: 10.1007/s00228-024-03744-z.